-
1.发明申请公开(公告)号：US20150079073A1
公开(公告)日：2015-03-19
申请号：US14251308
申请日：2014-04-11
申请人： Roche Glycart AG
IPC分类号： A61K39/395 , A61K45/06 , A61K31/136 , A61K31/7076 , A61K31/661
CPC分类号： C07K16/2887 , A61K31/136 , A61K31/137 , A61K31/661 , A61K31/675 , A61K31/7076 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/73 , A61K2300/00
摘要： The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
-
2.发明申请COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE 审中-公开含有FLUDARABINE和/或MITOXANTRONE的胶原蛋白CD20抗体的组合治疗公开(公告)号：US20140010804A1
公开(公告)日：2014-01-09
申请号：US13745652
申请日：2013-01-18
申请人： Roche Glycart AG
IPC分类号： A61K39/395 , A61K31/137 , A61K31/675 , A61K31/7076
CPC分类号： C07K16/2887 , A61K31/136 , A61K31/137 , A61K31/661 , A61K31/675 , A61K31/7076 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/73 , A61K2300/00
摘要： The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
摘要翻译： 本发明涉及非糖基化抗CD20抗体与氟达拉滨和/或米托蒽醌治疗癌症的联合治疗，特别是与含有氟达拉滨和/或非氟沙星的非糖基化人源化B-Ly1抗体的CD20表达癌症的组合疗法 米托蒽醌。
-
搜索结果
2 条记录 (耗时 0.012 秒)
